In short
Clinical trials investigating Aclidinium Bromide are studying treatment options for people with chronic obstructive pulmonary disease (COPD). These trials focus on how well different inhaled treatments work, especially for high-risk patients, and measure clinical control, safety, and overall treatment benefit.
Key points
- Clinical trials investigating Aclidinium Bromide are focused on chronic obstructive pulmonary disease, especially high-risk GOLD B patients. The main study is a Phase 3 interventional trial with 1,028 participants. It compares Trelegy® with LABA-LAMA treatment to see which approach gives better clinical control. The main outcome checks whether patients stay controlled at all study visits over 12 months. The trial was completed and used a validated composite endpoint that includes stability and impact.
Trial overview
The source data describe one completed clinical trial investigating Aclidinium Bromide in people with chronic obstructive pulmonary disease (COPD). The study is called THE ANTES B+ STUDY and it tested whether triple therapy could improve clinical control better than LABA-LAMA treatment in a high-risk COPD group.
Condition and target population
The condition studied was Chronic Obstructive Pulmonary Disease, which is a long-term lung disease that makes breathing harder. The target group was high-risk GOLD B patients, also written as B+ in the study title.
This means the trial was not a general COPD study for all patients. It was focused on a more specific group of people with COPD who were considered higher risk.
Study design and phase
This was an interventional study, so researchers compared treatments rather than only observing patients. It was also described as open-label, which means the treatment choice was known to the study team and the patients.
The study was randomized and controlled, so participants were assigned to treatment groups by chance and one treatment plan was compared with another. It was a Phase 3 trial with 1,028 enrolled participants.
The trial was also described as pragmatic, meaning it was designed to reflect real-life treatment use as much as possible.
What was measured
The main outcome was whether there was an association between Trelegy® use and being a patient who stayed persistently controlled by clinical control at all study visits. To count as clinically controlled, a patient had to meet the criteria at month 3, 6, 9, and 12.
The study summary says that clinical control (CC) is a validated composite endpoint, which means it combines more than one measure into one overall result. In this trial, CC included two domains: stability and impact.
Treatments compared
The trial compared Trelegy® with LABA-LAMA treatment. LABA-LAMA is a combination treatment approach, and the trial used it as the comparison group against triple therapy.
The intervention list includes many inhaled medicines and brand names, but the main comparison described in the trial summary is Trelegy® versus LABA-LAMA treatment. The source data do not provide detailed results for each listed product in this record.
What the study is trying to show
The trial was designed to test whether Trelegy® could improve clinical control better than LABA-LAMA treatment in COPD B+ patients. The key idea was to see which treatment helped more patients stay controlled across the full 12-month study period.
Because the study was completed, the main value of this record is in showing what question the researchers asked and which patient group they studied. The source data do not include detailed outcome numbers or final comparative results.